WEBULL
WebtradeDownload

Insiders Who Sold Cartesian Therapeutics Made The Right Call As Market Cap Slides By US$33m

Simply Wall St · 3d ago

Insiders seem to have made the most of their holdings by selling US$259k worth of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock at an average sell price of US$6.82 during the past year. The company's market valuation decreased by US$33m after the stock price dropped 10% over the past week, but insiders were spared from painful losses.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Cartesian Therapeutics Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Independent Director Timothy Barabe bought US$206k worth of shares at a price of US$6.86 per share. Even though the purchase was made at a significantly lower price than the recent price (US$9.30), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

Over the last year we saw more insider selling of Cartesian Therapeutics shares, than buying. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for Cartesian Therapeutics

insider-trading-volume
NasdaqGM:RNAC Insider Trading Volume September 2nd 2026

I will like Cartesian Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Does Cartesian Therapeutics Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Cartesian Therapeutics insiders own 53% of the company, worth about US$150m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Does This Data Suggest About Cartesian Therapeutics Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Cartesian Therapeutics insider transactions don't fill us with confidence. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Be aware that Cartesian Therapeutics is showing 5 warning signs in our investment analysis, and 1 of those shouldn't be ignored...

Of course Cartesian Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.